## **Core Concept**
The question tests understanding of calcium channel blockers (CCBs) and their effects on the atrioventricular (AV) node, specifically in the context of treating supraventricular tachycardia (SVT). CCBs are classified into two main types based on their primary site of action: L-type calcium channels in cardiac and smooth muscle. Their effect on the AV node is crucial for managing SVT.

## **Why the Correct Answer is Right**
Verapamil (option **D**) is a non-dihydropyridine calcium channel blocker that primarily affects L-type calcium channels in the heart. It is known for its potent negative dromotropic effect, meaning it slows conduction through the AV node. This action makes it particularly useful in treating SVT by interrupting the reentrant circuit that often involves the AV node. Verapamil's effect on the AV node helps in converting SVT to a normal sinus rhythm or in controlling the ventricular rate.

## **Why Each Wrong Option is Incorrect**
- **Option A (Amlodipine):** Amlodipine is a dihydropyridine calcium channel blocker that primarily causes vasodilation by acting on smooth muscle. It has minimal effect on the AV node and is mainly used to treat hypertension and angina.
- **Option B (Nifedipine):** Like amlodipine, nifedipine is a dihydropyridine calcium channel blocker. It predominantly causes vasodilation and has little to no effect on AV node conduction, making it less suitable for treating SVT.
- **Option C (Nilvadipine):** Nilvadipine is also a dihydropyridine calcium channel blocker with potent vasodilatory effects. It does not significantly affect AV node conduction and is not typically used for treating SVT.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that for treating SVT, the goal is often to affect AV nodal conduction. Verapamil and another CCB, **Diltiazem**, are the two main calcium channel blockers used for this purpose. Verapamil is particularly noted for its efficacy in treating SVT and certain types of angina.

## **Correct Answer:** **D**. Verapamil.